T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Steven M. Horwitz, Stephen M. Ansell, Weiyun Z. Ai, Jeffrey A. Barnes, Stefan K. Barta, Jonathan E. Brammer, Mark W. Clemens, Ahmet Doǧan, Francine M. Foss, Paola Ghione, Aaron M. Goodman, Joan Guitart, Ahmad Halwani, Bradley M. Haverkos, Richard T. Hoppe, Eric D. Jacobsen, Deepa Jagadeesh, Allison Jones, Avyakta Kallam, Youn H. Kim, Kiran A. Kumar, Neha Mehta–Shah, Elise A. Olsen, Saurabh Rajguru, Sima Rozati, Jonathan Said, Aaron C. Shaver, Lauren Shea, Michi M. Shinohara, Lubomir Sokol, Carlos A. Torres‐Cabala, Ryan A. Wilcox, Peggy A. Wu, Jasmine Zain, Mary A. Dwyer, Hema Sundar
Abstract
Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of lymphoproliferative disorders arising from mature T cells, accounting for about 10% of non-Hodgkin lymphomas. PTCL-not otherwise specified is the most common subtype, followed by angioimmunoblastic T-cell lymphoma, anaplastic large cell lymphoma, anaplastic lymphoma kinase-positive, anaplastic large cell lymphoma, anaplastic lymphoma kinase-negative, and enteropathy-associated T-cell lymphoma. This discussion section focuses on the diagnosis and treatment of PTCLs as outlined in the NCCN Guidelines for T-Cell Lymphomas.